Latest Conference Articles

The TOLEDO study noted it also increased “on” time without troublesome dyskinesia.

No evidence of adverse events or significant safety concerns has surfaced.

The development was presented by David Eidelberg, MD, at the 21st International Congress of Parkinson's Disease and Movement Disorders.

Scores on key scales improved 20%–28% after 1 year of jejunal levodopa/carbidopa.

Patient- and clinician-rated outcomes were keys in supporting labeling claims.

The method alleviates the 2 drugs' strained efficacy over time during Parkinson's progression.

Benefit was seen in 5 countries regardless of SGLT2 inhibitor used.

Human antibody may substantially reduce need for insulin in patients with T1D.

RT002 could treat moderate to severe isolated cervical dystonia with 2 or fewer annual shots.

Kausik Ray highlights the differences between the ODYSSEY DM-INSULIN trial differ from previous trials of PCSK9 inhibitors.

Samuel Frank, MD, director of the Huntington's Disease Society America Centers of Excellence at the Beth Israel Deaconness Medical Center, discusses hitting the moving target of Huntington's treatment, and his research on deutetrabenazine for the rare disease.

Results have major worldwide implications for type 2 diabetes treatment.

New-generation insulin found to have comparable cardiovascular safety to insulin glargine and significantly reduce episodes of severe hypoglycemia.

Investigational levodopa form CVT-301 improves "off" period motor function.

Two pivotal studies on sotagliflozin were presented at the ADA’s 77th Scientific Sessions.

Insulin glargine 100 Units/mL and lixisenatide 33 mcg/mL combined lowered A1C levels by 1.09% to 2.41% after 30 weeks.

Metformin may reduce the risk of heart disease in adults with T1D.

ODYSSEY DM-DYSLIPIDEMIA is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.

ODYSSEY DM-INSULIN is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.

Merck and Pfizer have announced that VERTIS MET and VERTIS SITA met primary endpoints.

Patients who switched to insulin glargine 300 Units/mL were 57% less likely to experience hypoglycemia at 6-months.

Teens with T1D improved their A1C levels by frequent 2-way texting.

Severely obese American Indian children had a 12-times higher risk of developing T2D as normal-weight youth.

Boys who are overweight as children but normalize as young adults have the same risk of type 2 diabetes as men who were never overweight.

More than 3,000 original research presentations will be offered in a robust 5-day program.

A disease that affects the motor and cognitive system can be treated well by physical therapy and exercise, Daniel M. Corcos, PhD, said.

Daniel M. Corcos, PhD, discusses the value of routine balance intervention activities for Parkinson's disease patients at the 21st International Congress of Parkinson's Disease and Movement Disorders.

Aleksandar Videnovic, MD, associate professor at the Massachusetts General Hospital, discusses new patient monitoring opportunities and other methods of treatment for one of Parkinson's disease patients' most common symptoms.

BMS-986168 significantly reduces CSF free eTau.

A Phase II-B trial with early to moderate PD patients showed efficacy.